Intensity Therapeutics, Inc. Common stock (INTS) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 6.75
(+198.67%)
Based on the Intensity Therapeutics, Inc. Common stock stock forecast from 2 analysts, the average analyst target price for Intensity Therapeutics, Inc. Common stock is USD 6.75 over the next 12 months. Intensity Therapeutics, Inc. Common stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Intensity Therapeutics, Inc. Common stock is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Intensity Therapeutics, Inc. Common stock’s stock price was USD 2.26. Intensity Therapeutics, Inc. Common stock’s stock price has changed by -1.74% over the past week, +21.51% over the past month and -52.32% over the last year.
No recent analyst target price found for Intensity Therapeutics, Inc. Common stock
No recent average analyst rating found for Intensity Therapeutics, Inc. Common stock
Company Overview Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Read Less
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractor...Read More
Frequently Asked Questions About Intensity Therapeutics, Inc. Common stock (INTS) Stock
Based on ratings from 2 analysts Intensity Therapeutics, Inc. Common stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on INTS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for INTS is USD 6.75 over the next 12 months. The maximum analyst target price is USD 8.5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on INTS's stock to indicate if its overvalued.
The last closing price of INTS's stock was USD 2.26.
The most recent market capitalization for INTS is USD 0.03B.
Based on targets from 2 analysts, the average taret price for INTS is projected at USD 6.75 over the next 12 months.
This means that INTS's stock price may go up by +198.67% over the next 12 months.
We can't find any ETFs which contains Intensity Therapeutics, Inc. Common stock's stock.
As per our most recent records Intensity Therapeutics, Inc. Common stock has 5 Employees.
Intensity Therapeutics, Inc. Common stock's registered address is 1 Enterprise Drive, Shelton, CT, United States, 06484-4779.
You can get more information about it from Intensity Therapeutics, Inc. Common stock's website at https://www.intensitytherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Frequently Asked Questions About Intensity Therapeutics, Inc. Common stock (INTS) Stock
Based on ratings from 2 analysts Intensity Therapeutics, Inc. Common stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on INTS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for INTS is USD 6.75 over the next 12 months. The maximum analyst target price is USD 8.5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on INTS's stock to indicate if its overvalued.
The last closing price of INTS's stock was USD 2.26.
The most recent market capitalization for INTS is USD 0.03B.
Based on targets from 2 analysts, the average taret price for INTS is projected at USD 6.75 over the next 12 months.
This means that INTS's stock price may go up by +198.67% over the next 12 months.
We can't find any ETFs which contains Intensity Therapeutics, Inc. Common stock's stock.
As per our most recent records Intensity Therapeutics, Inc. Common stock has 5 Employees.
Intensity Therapeutics, Inc. Common stock's registered address is 1 Enterprise Drive, Shelton, CT, United States, 06484-4779.
You can get more information about it from Intensity Therapeutics, Inc. Common stock's website at https://www.intensitytherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INTS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
